Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 14;21(1):23.
doi: 10.1186/s12933-022-01460-5.

Diabetes and restenosis

Scott Wilson  1 , Pasquale Mone  1   2 , Urna Kansakar  1   2 , Stanislovas S Jankauskas  1   2 , Kwame Donkor  1 , Ayobami Adebayo  1 , Fahimeh Varzideh  1   2 , Michael Eacobacci  1 , Jessica Gambardella  2   3 , Angela Lombardi  1 , Gaetano Santulli  4   5   6
Affiliations
Review

Diabetes and restenosis

Scott Wilson et al. Cardiovasc Diabetol. .

Abstract

Restenosis, defined as the re-narrowing of an arterial lumen after revascularization, represents an increasingly important issue in clinical practice. Indeed, as the number of stent placements has risen to an estimate that exceeds 3 million annually worldwide, revascularization procedures have become much more common. Several investigators have demonstrated that vessels in patients with diabetes mellitus have an increased risk restenosis. Here we present a systematic overview of the effects of diabetes on in-stent restenosis. Current classification and updated epidemiology of restenosis are discussed, alongside the main mechanisms underlying the pathophysiology of this event. Then, we summarize the clinical presentation of restenosis, emphasizing the importance of glycemic control in diabetic patients. Indeed, in diabetic patients who underwent revascularization procedures a proper glycemic control remains imperative.

Keywords: ACS; BMS; CABG; DES; Diabetes; Endothelial dysfunction; Epidemiology; Hyperglycemia; PCI; Restenosis; STEMI; Stent; VSMC.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, Green J, Huang E, Isaacs D, Kahan S, et al. Cardiovascular disease and risk management: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Supplement_1):S144–S174. - PubMed
    1. Cahn A, Wiviott SD, Mosenzon O, Goodrich EL, Murphy SA, Yanuv I, Rozenberg A, Bhatt DL, Leiter LA, McGuire DK et al. Association of baseline HbA1c with cardiovascular and renal outcomes: analyses from DECLARE-TIMI 58. Diabetes Care 2022. - PubMed
    1. Chen S, Huang Z, Chen L, Zhao X, Kang Y, Lai W, Lu X, Zhou Y, He Y, Huang H, et al. Does diabetes mellitus increase the short- and long-term mortality in patients with critical acute myocardial infarction? Results from American MIMIC-III and Chinese CIN cohorts. Front Endocrinol (Lausanne) 2021;12:797049. - PMC - PubMed
    1. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17(1):83. - PMC - PubMed
    1. Fishman SL, Sonmez H, Basman C, Singh V, Poretsky L. The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review. Mol Med. 2018;24(1):59. - PMC - PubMed

Publication types

MeSH terms